44 results about "Lung infection" patented technology

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention belongs to the technical field of nano diagnosis and treatment agents, and particularly relates to a preparation method and application of a multi-field response type nano diagnosis and treatment agent, the preparation method of the multi-field response type nano diagnosis and treatment agent comprises a core layer, a middle shell layer and an outer wrapping layer, the core layer is DCNPs, the middle shell layer is Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs, and the outer wrapping layer is an Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs. And the outer coating layer is HA which is coated on the outer side of the Nd < 0.03 > Fe < 0.97 > Se < 2 >. According to the invention, a multi-mode therapy of membrane structure defect induction-oxidative stress-metabolism interference-energy blocking can be realized, the mucous barrier penetrating ability is good, the retention ability of DNH in a pulmonary infection focus is improved, efficient drug delivery is realized, real-time NIR-II diagnosis can be assisted, and the application prospect is wide. The efficient treatment of lung bacterial infection diseases is realized.

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Compositions, kits, and systems are disclosed that contain at least one senolytic agent. The compositions, kits, and systems may be utilized, for example, in a method of treating at least one lung infection in a patient. In a particular (but non-limiting) embodiment, the compositions, kits, and systems may be utilized in a method of treating at least one infection in a cystic fibrosis patient.

The present disclosure relates to a lung infection area segmentation method and device, an electronic device and a storage medium. The method comprises: performing feature extraction processing on a lung image to obtain a plurality of high-level features; performing multi-scale fusion processing on the high-level features to obtain high-level enhanced features; performing global information extraction on the high-level enhanced features to obtain global guidance features; and performing multi-layer feature interaction processing on the high-level features by using the global guidance features to obtain lung features, wherein the lung features are used to represent a lung infection area of the lung image. The embodiments of the present disclosure can improve the lung infection area segmentation accuracy.

Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed. Kits including tafenoquine and means for testing for a viral infection are disclosed.

The invention discloses a polyclonal antibody for treating pulmonary infection as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: culturing pathogenic bacteria causing pulmonary infection by taking pig lung tissues as a culture medium, collecting the tissues, and homogenizing to obtain homogenate; performing antigen extraction and purification treatment on the homogenate, and performing inactivation treatment to obtain an inactivated antigen; immunizing a horse with the inactivated antigen, and collecting and separating to obtain serum; and carrying out antibody extraction and purification on the serum to obtain the polyclonal antibody. The prepared polyclonal antibody has the advantages of strong neutralization broad spectrum, high neutralization activity and good pulmonary infection treatment effect.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.

The invention discloses a composition, a kit and a detection method for detecting pulmonary infection pathogens. The composition comprises at least one of a component A, a component B, a component C and a component D, the component A comprises a primer pair SEQ ID NO: 1-2 and a probe SEQ ID NO: 3; detecting bordetella pertussis by the component A; the component B comprises a primer pair SEQ ID NO: 4-5 and a probe SEQ ID NO: 6; the component B is used for detecting Nocardia; the component C comprises a primer pair SEQ ID NO: 7-8 and a probe SEQ ID NO: 9; detecting cryptococcus neoformans by the component C; the component D comprises a primer pair SEQ ID NO: 10 to 11 and a probe SEQ ID NO: 12; the component D is used for detecting acinetobacter baumannii. The composition for detecting the pulmonary infection pathogens provided by the invention can detect and distinguish at least one of bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, has higher sensitivity, specificity and precision, can accurately and quickly detect bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, and can be used for detecting the pulmonary infection pathogens. The detection efficiency is improved, the detection period is shortened, and detection is convenient.

The present invention relates to a compound of formula (I) and its use in a method of treatment of a viral infection, particularly of a viral lung infection. The present invention further relates to pharmaceutical compositions comprising the compound of formula (I).

The invention discloses an antibiotic pharmaceutical composition for inhalation and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the antibiotic pharmaceutical composition comprises the following raw materials by weight: 1-20 parts of an antibiotic drug, 1-3 parts of an osmotic pressure regulator, 0-30 parts of an alcohol compound, 0.1-50 parts of a pH regulator, and 1-250 parts of a solvent. Furthermore, the pH regulator is at least one of hydrochloric acid, sulfuric acid, sodium hydroxide, citric acid, sodium citrate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium phosphate and phosphoric acid; according to the antibiotic pharmaceutical composition for inhalation, the components of the preparation are simple, a traditional stabilizer does not need to be added, the antibiotic medicine is prepared into a solution, the solution is combined with an atomizer, the surface tension of liquid medicine is reduced by optimizing a preparation prescription, and the medicine delivery rate, the total delivery amount and the effective delivery percentage during aerosol inhalation are remarkably increased; more drugs can directly reach the lung infection focus, and precise treatment is achieved.

The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and / or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

This invention relates to the field of medical data processing technology, specifically to a lung infection status early warning system based on medical big data. The system captures the flow velocity response before and after expiratory pressure regulation, and uses regularized inversion to deconstruct the time-domain signal, which is disturbed by respiratory rate, into a standardized sequence of measured lung unit volumes. Subsequently, it constructs a theoretical distribution benchmark of purely elastic recoil using measured high-pressure data. By constructing a transmission cost matrix reflecting the shear characteristics of non-Newtonian fluids, it uses an optimal transmission algorithm to calculate the optimal transmission strategy that reshapes the theoretical distribution into the measured distribution. Finally, it analyzes the topological entropy and transmission energy consumption of this transmission strategy to extract obstruction features and generate an early warning. This invention utilizes a rheological model to specifically quantify the viscosity and focal distribution of fluid within the airway, effectively differentiating between physical pulmonary edema and biological airway obstruction at an early stage.

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

This specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. Pulmonary fibrosis may be idiopathic or may occur after a lung infection. The lung infection may be caused by SARS-CoV-2. As a result of treatment, lung function is stabilized or improved. One aspect is a method for treating fibrosis that comprises the step of administering a Gli1 inhibitor. Inhibition of Gli1 may be indirect. In some embodiments, an SMO inhibitor is used to indirectly inhibit Gli1. In some embodiments, means for inhibiting SMO are used to indirectly inhibit Gli1.

The invention relates to the technical field of biological information detection, in particular to a metagenome sequencing diagnosis method and system for Aspergillus pulmonary infection, and the method comprises the following steps: acquiring lavage fluid lysis monitoring data, adjusting shear power output, analyzing fluorescence accumulation trend, adjusting temperature control frequency and substrate interval, identifying mutation points and constructing indexes, screening entropy inversion fragments, and obtaining the metagenome sequencing diagnosis result of Aspergillus pulmonary infection. According to the method, through dynamic matching of the lysate flow rate and the shearing power, the nucleic acid release balance is improved, the temperature control frequency and the substrate interval are adjusted according to the fluorescence signal accumulation trend in the amplification stage, the reaction equilibrium state is established, and the amplification deviation is corrected; and identifying a mutation boundary and reconstructing an index hierarchy according to basic group joint distribution and feature vector change, judging and screening feature sections in combination with information entropy inversion, establishing a probability convergence structure based on coverage depth and repetition frequency, and realizing stable identification of pathogen features and convergence output of classification confidence.

To provide a dried powder formulation of caveolin-1 peptide and a method for using the same. [Solution] Compositions comprising the caveolin-1 (Cav-1) peptide are provided herein. Furthermore, methods for using the Cav-1 peptide for the treatment of lung infections or acute or chronic lung injury, particularly pulmonary fibrosis, are provided. In a first embodiment, a pharmaceutical composition comprising a dry powder of the peptide is provided, wherein the peptide comprises one of the sequences of SEQ ID NOs: 2 to 20. In some embodiments, the peptide has an amino acid length of 7 to 20. In a particular embodiment, the peptide comprises the amino acid sequence of SEQ ID NO: 2.

Devices and methods are described for disinfection of pathogenic organisms using pulsed DC field electroporation. For example, this disclosure describes disinfection of pathogenic organisms using pulsed DC field electroporation for lung infection treatment, blood infection treatment, sterilization, and respirators.

This application discloses a sputum suction nursing device for lung infections, belonging to the field of medical devices. The device includes a suction nozzle, a negative pressure mechanism at one end of the suction nozzle, a suction tube at the other end of the suction nozzle, and a collection bag for collecting sputum. The collection bag is attached to the suction tube, and a three-way connector fixedly inserted into the collection bag and communicating with the suction tube. The end of the three-way connector away from the suction tube is connected to the suction nozzle. By designing the collection bag on the suction tube, making it a disposable item along with the suction tube, the risk of the suction nozzle being contaminated by sputum is greatly reduced. On the one hand, this avoids bacterial growth due to incomplete cleaning, ensuring the health and safety of patients and reducing the possibility of cross-infection. On the other hand, it avoids discomfort experienced by the person cleaning the sputum-contaminated suction nozzle, improving the operational experience of medical staff or nurses. Simultaneously, the use of disposable components improves the overall hygiene standards of the nursing process and enhances the patient's user experience.

The application discloses a kind of nitric oxide donor type raw ginger exosome fusion liposome nanodelivery system and its preparation method and application, the nanodelivery system uses super flow control chip technology to nitric oxide precursor, two stearyl phosphatidylcholine, cholesterol, tobramycin, self-assembly, and then prepared by extrusion method and raw ginger exosome membrane fusion.The drug delivery system has a significant breakthrough in mucus barrier and antibacterial efficacy, and can be applied to inhalation therapy for pseudomonas aeruginosa lung infection.The negative surface of the drug delivery system and the electrostatic repulsion of mucin in mucus, mPEG-PNTC generates NO due to GSH responsiveness, which has a gas motor effect, enhancing the effect of breaking through the airway mucus barrier, while the NO generated by mPEG-PNTC, through nitrosylation and oxidative stress, destroys bacterial biofilm, interferes with bacterial iron metabolism, and synergistically kills bacteria and destroys biofilm.The present application has the advantages of improving drug delivery efficiency and high-efficiency bactericidal function, and has broad clinical application prospects and development value in the field of bacterial lung infection treatment.

The invention relates to the technical field of biological medicines, in particular to application of an METTL3 inhibitor in preparation of a medicine for enhancing antibacterial immunity of lungs. The m6A modification level of the AMs is regulated and controlled through an active immune enhancement scheme based on in-vivo pretreatment of an m6A inhibitor (STC-15), so that the ability of the AMs to swallow and remove bacteria is enhanced, and a brand-new host-oriented treatment thought is provided for resisting pulmonary infection.

The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist, HFO propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides a specific container and a valve system comprising internally coated canister and a valve for storing the composition. The invention also provides a pharmaceutical composition comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.

The invention discloses application of astragalus membranaceus, dendrobium nobile and hawthorn granules in preparation of a new coronavirus infection medicine, and belongs to the field of medicine. The invention mainly protects the application of the astragalus membranaceus and dendrobium nobile haw particles in preparation of medicines for preventing, relieving, inhibiting or treating new coronavirus infection, and the astragalus membranaceus and dendrobium nobile haw particles have the effect of inhibiting SARS-CoV-2 infection, and can obviously inhibit the infection of in-vitro SARS-CoV-2 pseudovirus on A549 cells and the lung infection of in-vivo SARS-CoV-2 pseudovirus on C57BL6 / J mice overexpressing hACE2 protein. The effect of the astragalus membranaceus and dendrobium nobile hawthorn granules is not disclosed in the prior art, no technical enlightenment exists, and the astragalus membranaceus and dendrobium nobile hawthorn granules have outstanding substantive features and remarkable progress. Therefore, the compound has an application prospect of being developed into an anti-SARS-CoV-2 infection medicine.

The invention relates to the technical field of postoperative auxiliary sputum excretion, in particular to an esophageal cancer postoperative pulmonary infection auxiliary sputum excretion device which comprises a bottom plate, a sealing groove is formed in the upper end of the bottom plate, a flow guide pipe is installed in the sealing groove, a rubber plug is rotationally arranged in the flow guide pipe and is semicircular, one end of the flow guide pipe is communicated with an air pump, and the other end of the flow guide pipe is communicated with an air outlet. One end of the flow guide pipe is communicated with a sealing groove, the other end of the flow guide pipe is communicated with a suction pipe, the two sides of the flow guide pipe are each provided with an air extraction opening, and the two sides of the sealing groove are each communicated with an air inlet. Compression or friction and adsorption caused by the fact that the air suction end of the suction pipe is attached to the esophageal wall for a long time are reduced, so that discomfort such as pain or nausea is reduced, the risk of damage to esophageal mucosa is reduced, meanwhile, continuous traction and negative pressure adsorption to normal tissue in the esophagus can be reduced through intermittent suction, and the esophageal mucosa is prevented from being damaged. Other injuries caused by relatively fragile esophagus of the patient after the operation are prevented.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The invention provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases. 20 26 20 53 78 07 J ul 2 02 6 2 0 2 6 2 0 2 6 2 0 5 3 7 8 0 7 J u l